Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $49.15 million. The enterprise value is $33.38 million.
| Market Cap | 49.15M |
| Enterprise Value | 33.38M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 16.22 million shares outstanding. The number of shares has increased by 9.49% in one year.
| Shares Outstanding | 16.22M |
| Shares Change (YoY) | +9.49% |
| Shares Change (QoQ) | +18.25% |
| Owned by Insiders (%) | 16.45% |
| Owned by Institutions (%) | 11.90% |
| Float | 14.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 890.64 |
| Forward PS | 120.46 |
| PB Ratio | 3.91 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 604.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.59 |
| Quick Ratio | n/a |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -193.00% and return on invested capital (ROIC) is -163.56%.
| Return on Equity (ROE) | -193.00% |
| Return on Assets (ROA) | -123.20% |
| Return on Capital (ROIC) | -163.56% |
| Revenue Per Employee | $1,903 |
| Profits Per Employee | -$767,846 |
| Employee Count | 29 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $79,275 in taxes.
| Income Tax | 79,275 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.05% in the last 52 weeks. The beta is 0.43, so GANX's price volatility has been lower than the market average.
| Beta (1Y) | 0.43 |
| 52-Week Price Change | -41.05% |
| 50-Day Moving Average | 3.99 |
| 200-Day Moving Average | 3.51 |
| Relative Strength Index (RSI) | 32.74 |
| Average Volume (30 Days) | 163,087 |
Short Selling Information
The latest short interest is 149,596, so 0.92% of the outstanding shares have been sold short.
| Short Interest | 149,596 |
| Short Previous Month | 138,129 |
| Short % of Shares Out | 0.92% |
| Short % of Float | 1.05% |
| Short Ratio (days to cover) | 1.28 |
Income Statement
In the last 12 months, GANX had revenue of $55,180 and -$22.27 million in losses. Loss per share was -$1.71.
| Revenue | 55,180 |
| Gross Profit | 55,180 |
| Operating Income | -22.25M |
| Pretax Income | -22.19M |
| Net Income | -22.27M |
| EBITDA | -22.10M |
| EBIT | -22.19M |
| Loss Per Share | -$1.71 |
Balance Sheet
The company has $16.79 million in cash and $1.03 million in debt, giving a net cash position of $15.77 million or $0.97 per share.
| Cash & Cash Equivalents | 16.79M |
| Total Debt | 1.03M |
| Net Cash | 15.77M |
| Net Cash Per Share | $0.97 |
| Equity / Book Value | 12.58M |
| Book Value Per Share | 0.78 |
| Working Capital | 12.83M |
Cash Flow
In the last 12 months, operating cash flow was -$18.87 million and capital expenditures -$15,358, giving a free cash flow of -$18.88 million.
| Operating Cash Flow | -18.87M |
| Capital Expenditures | -15,358 |
| Free Cash Flow | -18.88M |
| FCF Per Share | -$1.45 |
Margins
Gross margin is 100.00%, with operating and profit margins of -40,328.26% and -40,354.33%.
| Gross Margin | 100.00% |
| Operating Margin | -40,328.26% |
| Pretax Margin | -40,210.67% |
| Profit Margin | -40,354.33% |
| EBITDA Margin | -40,059.20% |
| EBIT Margin | -40,210.67% |
| FCF Margin | -34,217.53% |
Dividends & Yields
GANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.49% |
| Shareholder Yield | -9.49% |
| Earnings Yield | -45.31% |
| FCF Yield | -38.42% |
Analyst Forecast
The average price target for GANX is $8.50, which is 180.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 180.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GANX has an Altman Z-Score of -2.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.79 |
| Piotroski F-Score | 2 |